Redmile Group, a hedge fund and private equity manager, led a $150m Series D funding round in Mammoth Biosciences, a biotech company. Additional investors included Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX and Plum Alley. “We’ve had a momentous year at Mammoth, which includes the maturation of our wholly-owned CRISPR platform for breakthrough therapeutic applications and partnerships with industry leaders that have accelerated the validation of our diagnostic technology in the real world,” Trevor Martin, Mammoth Biosciences Co-Founder and CEO.